Monday, January 28, 2013

CPRIT HAS BEEN AUDITED


An Audit Report on Grant Management at the Cancer Prevention and Research Institute of Texas and Selected Grantees




January 2013
Report Number 13-018

Overall Conclusion

The Cancer Prevention and Research Institute of Texas (CPRIT) should significantly improve the transparency and accountability of its grant management processes. Weaknesses in CPRIT's processes reduce its ability to properly award and effectively monitor its grants. Specifically, CPRIT should address deficiencies in the following areas:
- Making award decisions.
- Evaluating grant applications.
- Verifying compliance with matching funds requirements.
- Processing payments to grantees.
- Monitoring grantees' expenditures.
- Assessing and measuring research progress.
- Managing contract agreements with grantees.
Making Award Decisions
CPRIT should ensure that all award decisions are free from real or apparent conflicts of interest. The executive director discussed award recommendations with certain members of the oversight committee prior to presenting the recommendations to the full oversight committee. Also, CPRIT’s chief scientific officer, chief commercialization officer, and director of scientific review had office locations on the campuses of higher education institutions that received CPRIT awards. The chief scientific officer, the chief commercialization officer, and the director of scientific review are responsible for managing the peer review process for grant applications in their respective areas. In addition, auditors identified two members of CPRIT's commercialization review council with financial and personal interests in certain grantees. Specifically:
- One member of the commercialization review council was also a member of the board of directors for a grantee that received a $25.2 million research award from CPRIT. According to CPRIT's records, that individual did not participate in the review of the grant application for that grantee.
- Another member of the commercialization review council provided consulting services to two applicants applying for Texas life sciences incubator commercialization grants. That individual was not listed as participating in the review of grant applications for incubator grants, and neither applicant ultimately submitted a formal application for an incubator grant.
CPRIT also reported that it does not receive financial information about donors to the CPRIT Foundation or the amounts of the donations. Without that information, CPRIT has no assurances that it is not awarding grants to the CPRIT Foundation donors, which could create a conflict of interest. The General Appropriations Acts (81st and 82nd Legislatures) state that an individual; an organization; or an employee, officer, or director of an organization that makes a contribution to the CPRIT Foundation, or a person who has second-degree consanguinity or affinity to an employee of CPRIT, is not eligible to receive grants from CPRIT.
CPRIT's lack of controls for ensuring there are not any business and professional relationships between its peer reviewers and grantees impairs CPRIT's ability to assure the public that its award decisions are not improperly influenced.
Evaluating Grant Applications
CPRIT should ensure that its policies and procedures for evaluating grant applications are up to date and consistently followed. In addition, CPRIT should maintain records of all reviews that are performed.
Auditors could not verify that CPRIT consistently followed its process for withdrawing grant applications from the peer review process. CPRIT did not have reliable data to support grant applications that were withdrawn (see Chapter 1-B for more information).
Auditors identified the following significant issues for three grant applications tested:
- The Statewide Clinical Trials Network of Texas (CTNeT) received a $25.2 million research grant from CPRIT even though CTNeT did not exist at the time the grant was awarded. The CTNeT grant was the largest single grant that CPRIT had awarded as of June 2012. CPRIT originally awarded the grant to the University of Texas M.D. Anderson Cancer Center in June 2010. Subsequent to the award, CTNeT was formed and registered to become a Texas-based non-profit company in August 2010 and CPRIT executed a grant agreement with CTNeT in September 2010. It is unclear what allowed CPRIT to transfer the award from the University of Texas M.D. Anderson Cancer Center to CTNeT. CPRIT also did not have documentation to support that the scientific review council recommended the original application for a grant.
- CPRIT awarded a $20.0 million commercialization grant to the Houston-Area Translational Research Consortium (HATRC) and the Institute for Applied Cancer Science (IACS). Neither the HATRC grant application nor the IACS research proposal received scientific, due diligence, or intellectual property reviews. CPRIT reported that it rescinded the award in May 2012 after IACS requested to resubmit its research proposal for commercialization and scientific reviews.
- CPRIT awarded an $11.0 million commercialization grant to Peloton Therapeutics Inc. (Peloton, formerly Damascus Pharmaceuticals), whose application did not receive scientific, commercialization, due diligence, or intellectual property reviews.
Auditors reviewed the peer review scores for 218 (5.9 percent) of the 3,698 grant applications CPRIT reported receiving from September 2009 through June 2012 through the CPRIT Application Receipt System. Auditors identified four applications for which the peer review scores were not consistent with receiving a grant recommendation. CPRIT also did not have documentation to support the factors that peer reviewers used in making grant recommendations to CPRIT's executive director.
In addition, CPRIT did not document its review of recruitment grant applications or maintain records of those reviews in its Peer Review Management Information System. Recruitment grants are for the recruitment of investigators with the ability to make outstanding contributions to the field of cancer research, promote inquiry into new areas, foster collaboration, and stimulate growth in the field. Select scientific review council members manually review the recruitment grant applications; however, the only documentation maintained was a one-page summary statement that recommends the award of a recruitment grant. As of August 2012, CPRIT had awarded 60 recruitment grants totaling $184.9 million.
By not ensuring that all grant applications are properly evaluated and documented, CPRIT weakens its ability to ensure that its award decisions best align with the agency's mission.
Verifying Compliance with Matching Funds Requirements
CPRIT should verify the accuracy and availability of the matching funds its grantees report. The Texas Constitution, Article III, Section 67 (a)(3)(i), requires that before CPRIT awards a grant, the grantee must have funds equal to one-half the amount of the grant dedicated to the research that is the subject of the grant. CPRIT requires grantees to certify the amount of matching funds available for research at (1) the time of contract execution and (2) on an annual basis thereafter. However, CPRIT did not verify the accuracy and availability of the matching funds reported. In addition, during site visits to five grantees, auditors identified two methodologies, permitted by CPRIT, that allow a grantee to report funds that were not used on a CPRIT-funded research project as matching funds. Specifically:
- During interviews with auditors, staff at the University of Texas M.D. Anderson Cancer Center, the University of Texas Southwestern Medical Center, and the Baylor College of Medicine reported that the matching funds those institutions reported to CPRIT were based on the total amount of funding available to them for cancer research, excluding CPRIT funding. However, those reported matching funds were not dedicated to CPRIT-funded research projects. As of August 2012, those three institutions had received a combined 331 awards totaling $402.4 million.
- CTNeT, which received a $25.2 million research grant, did not dedicate $12.6 million in matching funds as required. Instead, CPRIT accepted certifications that the University of Texas M.D. Anderson Cancer Center and the Baylor College of Medicine would fulfill CTNeT's matching funds requirements for the first and second year of the grant agreement term, respectively. However, CTNeT did not receive those reported matching funds. For the first year of the CTNeT grant, CTNeT reported that the CPRIT grant accounted for 98.0 percent of its total revenue.
Processing Payments to Grantees
CPRIT should establish requirements to help ensure the appropriateness of advance payments and reimbursements it makes to grantees. Specifically:
- Advance payments. CPRIT's policies and procedures specify that CPRIT will distribute funds on a reimbursement basis. However, it made advance payments that totaled $40.2 million to 10 grantees from September 2008 through August 2012.
- Reimbursements. CPRIT relies on quarterly financial status reports and supporting documentation that grantees submit for reimbursement payments. However, CPRIT did not always obtain sufficient documentation from grantees to support the appropriateness of the reported expenditures. For 85 (84.1 percent) of the 101 reimbursements tested, or $9.4 million in reimbursements, CPRIT did not obtain documentation such as time sheets, invoices, contracts, and bill records to support the reimbursed expenditures. For those 85 reimbursements, grantees typically provided CPRIT with spreadsheets that summarized the expenditures.
Monitoring Grantees' Expenditures
CPRIT should improve its processes for monitoring grantee expenditures. CPRIT requires grantees to submit quarterly financial reports on research expenditures associated with awarded grants. In addition, CPRIT established a desk review process to assess grantees’ financial controls and reported expenditures. However, CPRIT did not ensure that all grantees submitted financial reports in a timely manner, did not maintain a complete record of all the financial reports it received from grantees, and had not performed any desk reviews of 487 grants totaling approximately $683 million as of June 2012.
Assessing and Measuring Research Progress and Compliance with Grant Milestones
CPRIT should ensure that grantees submit all required annual progress reports by required due dates, and it should review those reports and document those reviews. While CPRIT developed monitoring tools for tracking the due dates and submissions of annual progress reports, CPRIT lacked documentation to support that it followed up with grantees for past due reports. For a sample of 20 grant agreements that auditors reviewed, CPRIT had not received 12 (60 percent) of 20 annual progress reports that were due from September 2011 through June 2012. CPRIT's records indicated that it had started following up with grantees about past due reports beginning in May 2012. In addition, CPRIT has not developed review criteria for evaluating and measuring a grantee's reported progress. Although CPRIT used its peer reviewers to evaluate the eight annual progress reports it received, the peer reviewers did not document whether a grantee's reported progress met grant milestones or whether any problems had been identified that could affect the grantee's ability to complete the research project. CPRIT reported that it received emails from the peer reviewers indicating that a review was complete and that no issues had been reported by reviewers.
CPRIT should improve its management of the CTNeT research grant and other administrative practices.
Auditors identified significant weaknesses in CPRIT's award decision and management of the $25.2 million research grant to CTNeT (see Chapter 3 for more information about this grant). Specifically:
- CTNeT's grant application did not receive a favorable peer review score. CPRIT evaluated grant applications on a scale of 1 to 9, with 1 being the highest. The CTNeT grant application received a peer review score of 4.64. Auditors reviewed the peer review scores for 44 other applications and identified 9 applications that were not awarded grants that received peer review scores ranging from 3.93 to 4.40.
- CPRIT has a role in CTNeT's business operations. CPRIT’s oversight committee chair, vice-chair, and executive director interviewed and hired CTNeT's chief operating officer before the contract was executed. In addition, CPRIT's executive director, chief scientific officer, and a member of CPRIT's commercialization review council are members of CTNeT's board of directors.
- CPRIT made $6.8 million in advance payments to CTNeT even though its grant agreement with CTNeT allowed only reimbursement payments.
- CTNeT did not comply with matching funds requirements and annual progress reporting requirements.
CPRIT’s relationship with CTNeT and its lack of enforcing contract requirements impair CPRIT's ability to ensure that CTNeT is properly using grant funds and complying with grant requirements.
CPRIT also should improve certain procurement and payment practices for vendors and other professional services.
CPRIT should strengthen its vendor procurement and payment practices to ensure that the services and costs for grant management services and virtual management company services are reasonable and necessary. Specifically:
- The costs for a five-year contract for grant management services increased from $15.7 million to $21.2 million (35.2 percent) within the first three years of the contract. The cost increases were based on amendments to the contract that increased the workload of the grant management services contractor and the development of a grant management system.
- The costs for the first two years of a four-year contract for virtual management company services increased from $1.5 million to $4 million, approximately 166.7 percent. The cost increases were based on amendments to include services management, an entrepreneur-in-residence program, salaries for additional executive positions that were added to the contractor's staff, and other direct costs.
CPRIT also did not consistently obtain sufficient documentation to support the appropriateness of honorarium payments it made to its peer reviewers. From September 2009 through June 2012, honorarium payments to peer reviewers were approximately $6.7 million. In addition, CPRIT lacked documentation to justify increases in honorarium payments to officers of its peer review committees. Also, auditors identified honorarium payment amounts for certain peer reviewers that may be significantly higher than the payment amounts that the National Cancer Institute pays its peer reviewers.
Auditors communicated other, less significant issues to CPRIT's management separately in writing. Those issues were related to administrative reporting discrepancies, the forms grantees use for reporting, reporting practices for certain grantees' payment practices, performance feedback to grantees, executing grant agreements, and management of peer reviewer rosters.
The Legislature should consider amending statutory requirements to improve the transparency and accountability of CPRIT.
The Legislature should consider statutory requirements to:
- Allow peer reviewers to provide their grant recommendations to the executive director and members of the CPRIT oversight committee at the same time.
- Clarify what funds can be used and the intended use of matching funds reported by grantees.
- Clarify whether contributions made by non-profit foundations affiliated with grantees are appropriate.
- Prohibit an interlocking directorate between CPRIT and the CPRIT Foundation.
- Prohibit CPRIT employees from serving on a grantee's board of directors and related foundations.
- Clarify the positions of the oversight committee's presiding officer and other officers, including the responsibilities and specific term of service for those positions.
- Allow members of the oversight committee to affirmatively vote to approve the executive director's recommendations.
- Remove the Attorney General and the Comptroller of Public Accounts from CPRIT's oversight committee so that their statutory duties and responsibilities would not be impaired.
- Allow the executive director to provide CPRIT's oversight committee, along with grant recommendations, documentation of the other factors that the executive director considered when making grant recommendations.
- Require the CPRIT Foundation to make its records, books, and reports available to the public.

Contact the SAO about this report.

Download the Acrobat version of this report. (.pdf)

ASCO GI: Phase III Bevacizumab Results of the AVEX and TRIBE Trials

ASCO GI: Phase III Bevacizumab Results of the AVEX and TRIBE Trials

Plus: Avastin gets new indication from FDA for second-line treatment

By Anna Azvolinsky, PhD1 | January 28, 2013
1Freelance Science Writer and Cancer Network Contributor. Follow Her on Twitter


The same week that bevacizumab (Avastin) received a new indication for the treatment of metastatic colorectal cancer, results from two phase III trials involving the drug were presented at the American Society of Clinical Oncology 2013 Gastrointestinal Cancers Symposium (ASCO GI) held January 24–26 in San Francisco.

TRIBE Trial Results at ASCO GI 2013

Results of the phase III TRIBE trial—comparing bevacizumab plus FOLFOXIRI with bevacizumab plus FOLFIRI—for metastatic colorectal cancer patients who have not been previously treated with chemotherapy were presented at ASCO GI (abstract #336). First-line FOLFOXIRI combined with bevacizumab showed better efficacy compared with the combination with FOLFIRI. A phase II trial had initially showed promise of this combination.
(MORE: ASCO GI: Oral Chemo S-1 Increases Survival in Pancreatic Cancer, Japanese Study Shows)
Among 35 Italian centers, 508 patients were randomized one to one to either arm, which both included up to 12 cycles of 5 mg/kg bevacizumab followed by bevacizumab plus fluorouracil as a maintenance therapy.
The study met its primary endpoint—a median progression-free survival of 11.9 months was seen in the FOLFOXIRI arm compared with 9.5 months in the FOLFIRI arm (hazard ratio [HR] = 0.72; P = .001). Response rates were also higher for the FOLFOXIRI combination—64% compared with 53% in the FOLFIRI group (P = .015). Toxicities were as expected and comparable in the two groups.

AVEX Trial Results at ASCO GI 2013

Another bevacizumab phase III trial reported at the meeting was the AVEX trial of elderly metastatic colorectal cancer patients. The AVEX trial compared bevacizumab in combination with capecitabine or capecitabine alone in previously untreated patients 70 years or older (abstract #337).
According to the study researchers, this is the first randomized, prospective trial that has analyzed the benefit of bevacizumab specifically in elderly patients. The results show the combination may be a better treatment that improves elderly patient outcomes. The results validate the use of bevacizumab with capecitabine, a fluoropyrimidine, in elderly patients.
“[These results] confirm a benefit with increased response and tumor control,” said David Cunningham, MD, head of the gastrointestinal unit at the Royal Marsden Hospital in the United Kingdom, and the presenter of the study.
The open-label trial administered bevacizumab to one half of the patients at a 7.5 mg/kg dose every 3 weeks. A total of 280 patients (median age of 76) in 10 countries were part of the trial, which showed the combination prolonged progression-free survival compared with chemotherapy alone. Progression-free survival was 9.1 months for patients taking the combination compared with 5.1 months in the chemotherapy alone arm (HR = 0.53; P < .001).
Overall survival was also improved, but the difference between the two arms was not statistically significant—median overall survival was 20.7 months in the combination arm compared with 16.8 months for the capecitabine arm (HR = 0.79; P = .182). Grade 3 and higher adverse events were more frequent in the combination arm, but researchers said the regimen was generally well tolerated. Grade 3 or higher toxicities were seen in 59% of patients taking bevacizumab plus capecitabine compared with 44.1% of patients taking capecitabine alone.
“This trial result emphasizes that with appropriate selection, patients with advanced colorectal cancer, regardless of age, may benefit from chemotherapy and that the combination of capecitabine and bevacizumab represents a good option that has a favorable balance between efficacy against side effects,” said Cunningham.

Avastin Gets New FDA Indication for Second-Line Treatment

The US Food and Drug Administration (FDA) approved the use of bevacizumab (Avastin) as part of a new combination treatment for the second-line treatment of metastatic colorectal cancer. The drug is now approved in combination with a fluoropyrimidine-based irinotecan or oxaliplatin chemotherapy for metastatic colorectal cancer patients whose cancer has progressed after first-line treatment with a regimen that contains bevacizumab (ie, second-line treatment of bevacizumab/oxaliplatin for patients who received prior therapy of bevacizumab/irinotecan and vice versa).
Patients receiving the combination lived longer compared with those who switched to chemotherapy alone as a second-line treatment. Results showed a 19% risk of death reduction for patients on the combination therapy compared with standard chemotherapy alone (HR = 0.81; P = .0057) in the phase III ML18147 trial. The median overall survival was 11.2 months compared with 9.8 months. The results are published in the Lancet Oncology.
Bevacizumab is already approved in combination with chemotherapy as a first-line therapy for metastatic colorectal cancer patients and also as a second-line treatment in combination with FOLFOX4 (5-fluorouracil, leucovorin, and oxaliplatin).

DIET FAILURES

With any kind of diet, by the time you reach the 6-12 week mark,  the selected strategy has given you its maximum benefit.  Hopefully, by then you will have achieved the 10% reduction of your total weight which is the realistic goal to pursue.  If you did it right, 1-2 pound per week of weight loss, you would have lost at least 10 pound by now.  After this, maintenance is the challenge and your body's response is even more of a challenge.
The body wants to get back to the size it knows you can achieve.  Make no mistake, size is the major killer.  Just look at the tumor, when it gets too big, areas of necrosis soon happen because some areas will suffer ischemia.

Your body will start asking for food, will try to tell you that just this small thing will not be harmful, and it will tell this throughout the day.   TIMING, WHEN YOU CAN AFFORD TO EAT SOMETHING IS AN IMPORTANT STRATEGY TO PUT IN PLACE.  KEEP CONTROL OVER THIS.  REMEMBER ONE THING IS FOR SURE: BY THIS TIME, GROWTH HAS STOPPED AND THAT THIS IS ALREADY A GREAT GOAL ACHIEVED. KEEP IT THERE.

To go further down, avoid staying home near the refrigerator.  Go out, walk at the mall without money, just your ID! Or best go to the gym or call your support buddy.  When the diet effect is maximized, that is when you need to exercise the most, and that's when you need Calorie control the most, and your vitamins.  Whatever you do, do not increase your Carbohydrate intake, or any excess calories. Remember, you will not increase your weight doing this.  The body will fight back, trying to use what you have given it to its maximum advantage, using everything to its advantage, constipation will set in to prolong intestinal absorption and reduce stool size, but work on staying "regular".  Constipation is a proven risk of Colon cancer.  Take it out. At this stage, it also is hard to exercise. Your body will tell your brain not to exercise.  Any excuses will come to mind.  Double down and keep exercising.  A walk will be good any time.  Remember, staying home with the refrigerator in the house is one of the brain challenges.  If you do reach for the refrigerator, have safe options.  Very cold water, sweet non sugary options or a fruit.  Dried vegetable chips or low calorie nuts.  Here, frequency to the refrigerator needs to be controlled by a schedule.

So, schedule or time your eating, when you reach to eating, find options that are safe, and keep on moving or exercising; this should be your strategy.  And remember, if you do not increase your weight, that's an objective success already.  We will keep trying to find more and let you know!

Sunday, January 27, 2013

OVEREXPRESSION OF SQLE GENE ON CHROMOSOME 8,  MARKER OF PROLIFERATION?

One of the gene marked as proliferation genes is the SQLE, This gene located  at 8q24 was puzzling to me because it has a role in Sterol Biosynthesis.  I wonder why this gene was in the proliferation section.  Then it occurs to me that new cells need new cellular membranes.  Of course, you need to over-express this.
I should confess that sterol biosynthesis is a tremendous opportunity for cancer cure because research is advanced in this area.  I know the Trypanosome has been fought through this media.  Silencing SQLE.  Who would have thought....!

SPEAKING SLEEPING SICKNESS, MEDICATIONS USED TO TREAT THIS DISEASE INCLUDE ARSENIC DERIVATIVES.  IN AN EFFORT TO POTENTIATE THE ARSENICALS, COMBINATION WITH DFMO HAD BEEN TRIED, I WONDER IF ONE CAN USE THIS COMBINATION FOR TREATMENT IN ACUTE PROMYELOCYTIC LEUKEMIA?  WILL LOOK INTO THIS!
NOMENCLATURE OF THE GENES OF PROLIFERATION, STILL THE 3RD LAW,

1. ZWINT:

During cell division, separation of chromosome or chromosome  movement is not random, and follows microtubule tracks through an attachment at the Kinetochore. Kinetochore attaches the chromosome at its inner section, and the micotubule at the outer section.   protein components of the the Kinetochore include Dynein, a cytoplasmic protein that need to be recruited (phosphorylated) to the Kinetochore.  The ZWINT (at 10q21)with its interactor ZW10, serves as a substrate to AURORA B, helps globally with the Dynein recruitment  at the Kinetochore.   Disruption at the Kinetochore will foil cell division.
Expression of the ZWINT marks a proliferative phase in the cancerous process.

2. TTK
CANNOT DESCRIBE IT BETTER
"
This gene encodes a dual specificity protein kinase with the ability to phosphorylate tyrosine, serine and threonine. Associated with cell proliferation, this protein is essential for chromosome alignment at the centromere during mitosis and is required for centrosome duplication. It has been found to be a critical mitotic checkpoint protein for accurate segregation of chromosomes during mitosis. Tumorigenesis may occur when this protein fails to degrade and produces excess centrosomes resulting in aberrant mitotic spindles. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Nov 2009]

Genomic context

Location :
6q13-q21"
SOURCE  NCBI
 ------------------------------
RELATED GENES : THE CYCLIN DEPENDENT KINASE AND PLK-1
RELATED PATHWAY pRb PATHWAY.
THIS IS PROLIFERATION AT IT BEST, CANCER MUTATES THESE TO ESCAPE PROLIFERATION CONTROL

UPDATE ON TREATMENTS OF PERIPHERAL T CELL LYMPHOMA

3 AGGRESSIVE TYPES:
==================
1. PTLC- NOS
2. AITL: AngioImmunoblastic
3ALCL (Anaplastic large cell  (ALK +)  6% AND     alk NEGATIVE
CD30 , t(2,5)(p23,q25)
---------------------------------------------------------------------------------
1 Peripheral T cell lymphoma not otherwise specified
-PET
-Gene Profiling
treat it with EPOCH (CHOEP) or Etoposide based regimen followed by transplant
consider Romidepsin (upfront in Europe)
followed by Gemcitabine, Navelbine (Doxil)

Europeans give ACVBP +/- Romidepsin (Vindesin not available in the US)

refractory disease" FDA has released 3 drugs, their role and position is being evaluated"
=============
Romidepsin
Pralatrexate
CD30 positive - BRENTUXIMAB VEDOITIN
----------------------------------------------------------------------------------------------
2. some T cell lymphoma are clearly Indolent i.e Mycosis Fungoides (MF)
-------------------------------------------------------------------------------
3. Anaplastic Large cell Lymphoma
ALK negative
for Europeans ACVBP followed by transplant

USA, same paradigm as in PTCL NOS

FOR ALK POSITIVE -- CHOP  ALONE IS THE BEST NO TRANSPLANT (NO ETOPOSIDE NEEDED)   (THE GERMAN STUDY WAS RETROSPECTIVE )
CRIZOTINIB

PRALATREXATE AND ROMIDEPSIN HAVE BEEN USED IN CLINICAL TRIAL
---------------------------------------------------------------------------------------------------------
4. ANGIOIMMUNOBLASTIC

STEROIDS
SOME CLAIM CYCLOSPORINE (PARTICULARLY WHEN HEMOLYTIC ANEMIA)

IN EUROPE CHOP-ROMIDEPSIN

IN USA, GEMZAR
FOR THOSE WITH A COMPONENT OF CD20 POSITIVE, RITUXAN +STEROID

WHATEVER YOU DO, DON'T GIVE ADRIAMYCIN!
sCD163 and sTARC are disease response biomarkers for Hodgkin's lymphoma
As published in Clinical Cancer Research, combined sCD163 and sTARC are better markers of disease response in patients with Hodgkin's lymphoma undergoing first-line therapy than either marker alone. sCD163 reflected tumor burden during treatment, while sTARC was more significant upon completion of therapy.
GENETIC MUTATIONS GIVING FURTHER INSIGHT INTO HEMATOLOGIC MALIGNANCIES, POINTING OUT WHERE ABNORMALITIES ARE WHICH WHICH WILL IMPACT SIGNIFICANTLY RESEARCH FOR THERAPY.

While Multiple Myeloma seems to result from amplification of major pathways with Ubiquitinated molecule persistence being one of the major therapeutic interventions (as a result of proteasome inhibitors), most likely by feedback blockage of major pathways and mitotic check point arrests, Myelodysplasia and Leukemia are going purely NUCLEAR.  SF3B1 mutation now associated with Refractory Anemia with ring Sideroblasts and cases of Chronic lymphocytic leukemia, putw us square and fair into the realm of m-RNA splicing.  The new interest in SETBP1 ties some case of mental retardation to elevated risk of Anemia. (Schinzel-Giedion Syndrome).  But remember, the elevated risk of AML in Down Syndrome-Coincidence or similarity, is the question!

Finding abnormality in the PRPF8 gene in dysplasia and leukemia brings back and re-enforces that splicing abnormality may be a significant driver in these conditions.  These findings cast doubt that researchers pushing drugs treating myeloma in Leukemia treatment  may meet disappointment.  It is another animal all around!

Abnormality in CSMD1 gene (regulator in the complement system) caught our attention. Is this an insight into immunodeficiency in Dysplastic syndrome...?  we will follow-up!

Another gene PPFIA2 is down regulated by Androgen therapy in prostate cancer, if it is significant, can we use this as predictive indicator in a therapeutic strategy?

We can't seriously finish without talking about the RUNX-1: what a major target since differentiation lays here.  But is differentiation a meaningful target?  Remember, allowing these cells to fully mature may lead them to Apoptosis... so let's weigh this one! 

The future is exciting in Research!

Saturday, January 26, 2013

Adrenaline Funk by Clement Albert on Ubetoo

by Clement Albert
Adrenaline rushing in my veins


http://www.ubetoo.com/clementalbert/54807#.UQQiUGhzo7o.email
copy the link if it does not work!
---
This message was sent by drkcancerclinic@GMAIL.CON via http://addthis.com.  Please note that AddThis does not verify email addresses.

Make sharing easier with the AddThis Toolbar:  http://www.addthis.com/go/toolbar-em


A little music for relaxation can only do good!


PRELIMINARY DISCUSSION ON THE 4TH LAW. THE 4TH LAW IS BEST UNDERSTOOD AS THE SET OF FORCES THAT DRIVE THE CELL FUNCTIONS IN A PARTICULAR ELECTED DIRECTION.

THE 4TH LAW IS BEST UNDERSTOOD AS THE SET OF FORCES THAT DRIVE THE CELL FUNCTIONS IN A PARTICULAR ELECTED DIRECTION.
At molecular level, this is enforced by GENE AMPLIFICATION.  That is if the cell is going toward differentiation, the cell will make cellular processes to direct all the cellular function to that aim.  for specific cancer this equivalent to the notion of DRIVER Mutation.   Cellular functions are not totally random and living things do not stay still!  life is always on the go, and on the go for survival.  And once it has chosen a direction, it direct its functions toward an overall goal which at cellular level is to ensure survival.  The drive, the stamina, the direction is battery powered and purposeful!
In the cell that drive is powered and to ensure that it has direction,  AMPLIFICATION GENES go to work.

One good example of this is what happens with some Viruses.  A number of viruses when the enter the host cell, will incorporate their viral genome into the genome of the host to manage to use the host survival machinery to their advantage.  Insertion in the genome of the host sometimes is not enough to trigger the use of the Viral genome in the host machinery, the Virus has to recruit a "growth factor" most of the time called FACTOR-1 to ensure amplification of its genetic material.  (this is known for HIV infection)

In cancer cells, there are amplification genes toward the completion and survival of the cancerous process.
In lung and thyroid cancers, TTF-1 represent such a gene.  found amplified in about 10 % of tumors.  Scientist have had trouble defining its role.  But they know its AMPLIFICATION is bad news for the host.  It is a driver gene for the cancerous process.   In the cell, there are several levels of GENE AMPLIFICATIONS.

The first level is mission driven.  If the mission is to differentiate, this 4th law push to achieve the mission.
if the mission is to grow a cancer, the cell uses all its resources to make a "perfect cancer."  This means, tolerate error in the DNA multiplication, down-regulate the repair mechanism, down-regulate or mutate the  regulator of P53, MDM2. Amplify VGEF so that the tumor has plenty of good blood vessels.

The second level of amplification is actually originating from the stimulus, the cause of the transformation.  the cause could be a change in Oxygen level, a break of shorten Telomerase tail, Tumor growth factor (FGF-1), Cyclins, or an oncogenic mutation or break of DNA strands.  This will ultimately stimulate receptors with subsequent signal transduction pathways flow that could be amplified by way of  intensity of the signals, but also enzymatic up-regulation and nuclear transcription amplification.   Amplification can be then cancerous based, but also stimuli caused.

the 3rd amplification is what occurs at the DRIVER Mutation due to growth factors or increased catalytic rate from related enzymes.

It is hard to measure cancer driven gene Amplification.  Most of the study keeps taking Metothrexate and its mechanism of Resistance because amplification of Dehydrofolate Reductase is the mechanism of resistance.  every body focus on this enzyme to measure resistance.   But when you look at amplification at this various levels, it is not  hard to see that these measurements are missing the point or are just misleading.

We will discuss the relevant Genes under the section or Rubric "NOMENCLATURE".  Frankly speaking, we have not finished yet the genes for the 3rd law.

We are working hard at CRBCM!

New Norovirus Strain Hits US

Jan 24,2013
In the middle of a punishing influenza season, a new strain of norovirus from Australia has come on the scene, and it is not yet clear how nasty this bug will be, the Centers for Disease Control and Prevention (CDC) announced today.
In its latest Morbidity and Mortality Weekly Report, the CDC identified the Aussie newcomer as GII.4 Sydney. First spotted in March 2012, the strain already has triggered acute gastroenteritis outbreaks in the United Kingdom and other countries. During the last 4 months of 2012, GII.4 Sydney accounted for 53% of 266 norovirus outbreaks in the United States reported through an electronic laboratory surveillance system called CaliciNet. Roughly half of the Sydney outbreaks resulted from direct person-to-person transmission; another 20% were foodborne.
Two thirds of the US outbreaks of GII.4 Sydney have occurred in long-term care facilities.
The CDC stated that GII.4 Sydney appears to have replaced a previously dominant strain called GII.4 New Orleans. In general, GII.4 strains are associated with higher rates of hospitalization and death.
GII.4 Sydney strain of norovirus
The emergence of a new norovirus strain such as GII.4 Sidney often leads to "increased outbreak activity," but not all the time, according to the CDC. The agency said that it is premature to assess the relative magnitude of GII.4 Sydney because during the previous 3 winters, "the peak in reported norovirus outbreaks occurred in January." However, the CDC urged clinicians to be on the lookout for a potential rise in norovirus cases in the coming weeks.
"Proper hand hygiene, environmental disinfection, and isolation of ill persons remain the mainstays of norovirus prevention and control," the CDC noted.
The foremost clinical hazard of any norovirus infection — especially for the elderly — is dehydration caused by vomiting and diarrhea, said William Schaffner, MD, an infectious disease expert at Vanderbilt University Medical Center in Nashville, Tennessee.
In severe cases, Dr. Schaffner told Medscape Medical News, oral fluids and electrolyte replacement may need to give way to intravenous fluids. Patients also require attentive care lest a rush to the bathroom together with faint-headedness lead to a stumble, a fall, and a head injury, he said.
Morb Mortal Wkly Rep. 2013;62:55. Full text
Latest in Infectious Diseases

Friday, January 25, 2013

Op Ed from Vice Chair Barbara Canales



3:14 PM (49 minutes ago)

to me
The Cancer Prevention and Research Institute of Texas Foundation serves as the connecting link for public policy, community, and business leaders and is committed to strengthening and expanding the fight against cancer in Texas.

Is this email not displaying correctly?
View it in your browser.
CPRIT Foundation
Below is the Op Ed from CPRIT Foundation Vice Chair Barbara Canales
 that ran in the Houston Chronicle today. The CPRIT Foundation 
continues to operate under a process of integrity, intelligence and 
efficiency. We are encouraged by the strength and confidence of 
our Board, staff, and supporters.
Cancer Agency Committed to Clarity, Transparency
In recent months, the Cancer Prevention and Research Institute of 
Texas has come under the scrutiny of state leaders and Texas citizens.
In an effort to make all facts known and available to the public, the 
 CPRIT Foundation - the nonprofit created to support the mission 
of the institute - has found it imperative to make its role and 
purpose clear.
First, it is crucial to know that no taxpayer money is used to support
 the activities of the CPRIT Foundation. The foundation is funded 
entirely by private donations.
In an effort to provide complete transparency, a list of foundation
 donors has been made public and provided to members of the 
Texas Legislature, other public officials and members of the media.
Originally, the foundation adopted a donor bill of rights to protect
 the confidentiality of its donors. This is standard practice for
 foundations so that contributors are not added to call lists or 
targeted by other organizations seeking financial support. However,
 in light of recent developments, the foundation took this important
 step.
It is also important to note that the foundation plays no role in the
 institute's grant application or review process. It has made every
 effort available to the foundation to address potential donor 
conflicts, including prohibiting foundation donors from receiving
 grants from the institute.
In fact, contributions have been returned in cases where it has been determined a possible conflict may exist.
The CPRIT Foundation was established by the Legislature for good 
reason; to support the work of the institute by supplementing 
executive salaries, coordinating an annual scientific conference 
and promoting cancer prevention and research efforts alongside
 business and community leaders. The foundation exists solely
 for these administrative purposes. As organizations other than 
CPRIT have found, this model is necessary, and not uncommon,
 in achieving goals that are restricted by state agency regulations.
For example, the state Legislature correctly contemplated that 
CPRIT would not be able to attract the caliber of scientists needed
 to make it a first-class institute with the salaries allowed by the 
state of Texas. To recruit the best scientific minds in the country, 
CPRIT needs to offer a competitive salary, and that is only achieved
 by having a separate foundation that can supplement that 
compensation.
The CPRIT Foundation also coordinates and directs CPRIT's annual
 conference using private funds. This conference attracts the most accomplished and highly respected scientists in the world and 
nearly 1,000 attendees to our state to discuss the most advanced 
and cutting-edge developments in cancer prevention and research.
Throughout the year, the foundation staff also travels across the 
state to conduct meetings with advocates and community leaders.
 The foundation also organizes Cancer Day at the Capitol to raise 
awareness among state legislators and has coordinated an annual 
meeting in Washington to build relationships to recruit support 
and federal grants into our state.
The consulting firm selected to direct the efforts of the foundation,
 JHL Company, was chosen because of its proven success in 
fundraising and project management for both public and private 
entities.
The retainer for their services, which includes all operating 
expenses and overhead associated with the foundation, is 
less than 17 percent of the foundation's total income over a
 three-year period. This is comparable to other, similar foundations.
Members of the CPRIT Oversight Committee and the CPRIT 
Foundation Board of Directors serve as uncompensated volunteers.
 I serve on both, within the parameters of the original bylaws,
 because of my own personal connection to this terrible disease.
As an organization created to supplement the efforts of such an
 important cause, the foundation is committed to providing clarity, transparency and anything else that will help the institute continue
 its hard work in the fight against cancer.
Copyright © 2013 CPRIT Foundation, All rights reserved.
You are receiving this email because you opted in at our website or are a friend of CPRIT.
Our mailing address is:
CPRIT Foundation
P.O. Box 12631
Austin, TX 78711

Add us to your address book
Email Marketing Powered by MailChimp

FDA Approves Imatinib for Pediatric ALL

Nick Mulcahy
DisclosuresJan 25, 2013
 
The US Food and Drug Administration (FDA) today approved imatinib (Gleevec, Novartis) for the treatment of newly diagnosed pediatric acute lymphoblastic leukemia (ALL) that is Philadelphia chromosome (Ph) positive.
"We are pleased that the number of cancer medications for children is on the rise," said Richard Pazdur, MD, director of the Office of Hematology and Oncology Products at the FDA Center for Drug Evaluation and Research, in a press statement.
In 2011, imatinib was approved to treat children newly diagnosed with Ph-positive chronic myeloid leukemia (CML).
However, ALL is the most common type of pediatric cancer, affecting approximately 2900 children annually, according to the FDA.
The safety and effectiveness of imatinib for pediatric patients with Ph-positive ALL were established in a clinical trial that enrolled children (1 year and older) and young adults with very-high-risk ALL (>45% chance of experiencing complications from their disease within 5 years of treatment).
The 92 patients with Ph-positive ALL enrolled in the trial were divided into 5 treatment groups, with each successive group receiving imatinib plus chemotherapy for a longer period.
Fifty of the Ph-positive ALL patients received imatinib for the longest period, and 70% of these patients did not experience relapse or death within 4 years. In addition, patient deaths decreased with the increasing duration of imatinib treatment in combination with chemotherapy, according to the FDA.
The most common adverse effects observed in children with Ph-positive ALL treated with imatinib plus chemotherapy were decreased neutrophil levels, decreased blood platelets levels, liver toxicity, and infection.
Imatinib is a tyrosine kinase inhibitor that blocks cancer-promoting proteins, and should be used in combination with chemotherapy to treat pediatric Ph-positive ALL.
Imatinib has been a practice-changing drug in this setting, according to the Children's Oncology Group, which conducted the pivotal clinical trial.
According to the group's Web site, the preferred treatment for Ph-positive ALL before imatinib was stem cell transplantation followed by 3 to 6 months of chemotherapy. However, cure rates were less than 50% with this approach. Imatinib in combination with chemotherapy has doubled cure rates, and stem cell transplantation is no longer automatically considered to be the best way to treat children with Ph-positive ALL.
Imatinib was granted accelerated approval in 2001 by the FDA to treat patients with blast-crisis, accelerated-phase, or chronic-phase Ph-positive CML who have failed interferon-alpha therapy. The drug was also approved in 2012 for the treatment of adults whose Kit (CD117)-positive gastrointestinal stromal tumors (GIST) had been surgically removed.
 
Latest in Hematology-Oncology
FREE CPRIT MOVEMENT HAS BEEN CREATED!
PEOPLE AND INSTITUTIONS NEEDING FUNDING FOR CANCER RESEARCH CAN'T WAIT TO SEE CPRIT FREED FROM POWERS !
TALK TO YOUR LEGISLATORS ABOUT CPRIT FREEDOM!

In the meantime, Senator Kevin Eltife from Tyler is introducing legislation to stop CPRIT funding through sale of bonds.  He believes that CPRIT should plead its case yearly asking for general fund with a dance before the Finance and and Appropriation Committee. He reportedly believes tha,t with that dance, the scrutiny level will increase.  This point is as debatable as can be and may miss the point all together.   The Senate was there with their eyes opened when the deals were going on!  Somehow an annual report to the Senate cannot be hiding the bad deed?  No, you need just good old honesty in CPRIT leaders and fair balanced processes to solve the issues at hand at CPRIT!   One thing for sure, the Senator is reported to be consistent. He had similar position reportedly before the creation and passage of the law about CPRIT.  Give him that!
NICE QUOTES FROM THE LANCET!

VOLTAIRE :  "The art of Medicine consists of amusing the patient while nature cures the disease".
                even then, the new the truth, we have been found out!  patient have build in defense! we are just distracting him.....

PARCELSUS : "The art of healing comes from nature and not from the physician; Therefore, the physician must start from nature with an open mind"....

And here I am throwing the kitchen sink of chemotherapy instead of Target therapy.  Cure will come from the mastering of law of nature at cellular level . READ CAREFULLY!  CURE IS WITH US, LET'S OPEN OUR MIND!

CREDIT TO DANIEL KRELL, JUSTIN STEBBING!
IN DEPTH INVESTIGATION, BRAIN INJURY--CRBCM
(THIS IS PART OF A PROTOCOL SUBMITTED FOR RESEARCH)

After a trauma to the brain, and in a mature brain, excitatory messages or stimuli lead to the release of Glutamate at the pre-synaptic membrane.  Glutamate released forthwith, will go on to stimulate those well known post-synaptic ionotropic receptors (AMPAR and NMDAR).
The intensity of the post-synaptic stimulation is in fact related to the amount of  receptors clustered in the involved region of the post-synaptic membrane, and the intensity of the ion traffic in the ionotropic channels, leading to variation in the voltage dependent activation of post synaptic events.  This variation of activation and electric status linked to ion displacement has been summarized in the concept: "SYNAPTIC PLASTICITY".

Depending on the nature of subunits of the post-synaptic Receptor (content in NR2B), the post-synaptic event can be inhibitory or activating.  A global positive influx of Calcium through the channels mentioned above lead ultimately to a post-synaptic phosphorylation of the powerful ERK-MAP-Kinase signal transduction pathways with significant physiological consequences.

See, when stress is the initiating event, a particular member of the MAPK family called the C-jun will be awakened up.  The C-Jun terminal protein (JNK) will unveil all its might and strike by way of phosphorylation various substrates in the Nucleus, the Mitochondria and right there in the Cytosol.

In the Mitochondria, the stress and toxic induced C-jun lead to loss of MMP and induce  Cytochrome C release into the Cytosol with resulting activation of the Caspase cascade which leads to Apoptosis or NEURONAL DEATH.

At Nuclear and Cytoplasmic levels, C-jun downregulate Bcl-2, (and MCL-1), up regulate BAX which are pro-Apototic moves or processes, but it also induce pro-inflammatory (TNF alpha, Interleukin 6,8) Cyclins to cause death by Necrosis.  At Glial level, these pro-inflammatory cyclins leads to Neuro-Degeneration.

At CRBCM we believe that in this day in age, letting neurodegeneration set in without intervention is not only ignorant, but not responsible!!!!!  We got to act...respond somehow...our leaders are holding funds and holding us back!    SAY SOMETHING!!  MY READERS !

FREE CPRIT MOVEMENT HAS BEEN CREATED!
QUIZARTINIB ALLOWS TO BUY TIME BEFORE TRANSPLANT IN AML.
In AML patient with FLT3-ITD
46% complete response reported
27% partial response
--------------------------------------
73% total response rate per this account

IF you do not have the FLT3-ITD
32% CR
16% PR
----------------------------------
48% RR

Median duration of response 3 months for FLT3 positive
and 1.5 month for FLT3 negative

the drug is reported to be well tolerated.

*> In other Major news,
Eribulin had failed to best Xeloda overall
there was a positive trend  in triple negative breast cancer which is the focus of CRBCM

*Apixaban may become a valid option for DVT treatment
since it does not require monitoring
and it is not cleared by the Kidneys and therefore could be used in kidney failure patients!
SHORT NEWS FROM ASCO POST

*For years we have been telling women that 5 years of Tamoxifen is all they needed in the treatment of ER positive breast cancer.  We went on to tell them that prolonging the duration of Tamoxifen could only lead to more side effect.  So it is a bit of a surprise that all of the sudden the Oncology community has quickly embraced the new 10 years being recommended without any questions raised.  Had we been lying to women all this time?  who has been giving Tamoxifen for 10 years behind our back?

Published results suggest : "617 recurrences in women taking Tamoxifen for 10 years Vs 711 recurrences in women treated for 5 years".  Total observation time 10-14 years.   SO standard today is 10 years of Tamoxifen, no question asked!

*Ponatinib is the new Darling drug in CML and Philadelphia positive ALL
In a study published by DR Cortes 267 evaluated patients
56 % of those in Chronic phase CML achieved Major Cytogenetic response (Most of these were resistant to TKI.
and 57% of those in accelerated phase achieved a major hematologic response and 34% of those in Blast phase responded.
Remember the FDA has already approved the drug!

OMACETAXINE is also active in this disease!

*POMALIDOMIDE is the other wonder but this time in Myeloma
4mg given with 20 mg of Decadron as given in the study!
Also an Oral Proteasome inhibitor MLN9708 is under study with promising results

*For Invasive breast cancer, adjuvant radiation for 3 weeks equivalent to 5 weeks per a UK study!  People are still waiting for the RTOG to conclude its trial.

*Ibrutinib is the new darling drug in CLL
at 26 months, 96% progression survival in chemo-naive CLL
and 75% progression free survival  in relapse/refractory CLL/SLL

*QUIZARTINIB  BUY TIME TO TRANSPLANT